Celldex Therapeutics
CLDX60
$27.02arrow_drop_up3.01%$0.79
CLDX60
$27.02
arrow_drop_up3.01%Performance History
| Key Stats | |
|---|---|
| Open | $26.33 |
| Prev. Close | $26.22 |
| EPS | -2.58 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 25.71 | 27.12 |
| 52 Week Range | 22.11 | 53.18 |
| Ratios | |
|---|---|
| EPS | -2.58 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Celldex Therapeutics (CLDX)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Anthony S. Marucci M.B.A.
- Headquarters
- Hampton
- Employees
- 148
- Exchange
- NASDAQ
Keep an eye on Celldex Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Celldex Therapeutics 's (CLDX) price per share?
The current price per share for Celldex Therapeutics (CLDX) is $27.02. The stock has seen a price change of $0.79 recently, indicating a 3.01% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Celldex Therapeutics (CLDX)?
For Celldex Therapeutics (CLDX), the 52-week high is $53.18, which is 96.82% from the current price. The 52-week low is $22.11, the current price is 22.21% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Celldex Therapeutics (CLDX) a growth stock?
Celldex Therapeutics (CLDX) has shown an average price growth of -3.66% over the past three years. It has received a score of 28 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Celldex Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Celldex Therapeutics (CLDX) stock price performance year to date (YTD)?
As of the latest data, Celldex Therapeutics (CLDX) has a year-to-date price change of -33.14%. Over the past month, the stock has experienced a price change of -5.76%. Over the last three months, the change has been -27.31%. Over the past six months, the figure is -25.61%. Looking at a longer horizon, the five-year price change stands at 1.07K%.
help
Is Celldex Therapeutics (CLDX) a profitable company?
Celldex Therapeutics (CLDX) has a net income of -$141.43M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.63K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $6.88M, although specific revenue growth data is currently not available. Operating income is noted at -$154.54M. Furthermore, the EBITDA is -$171.06M.
help
What is the market capitalization of Celldex Therapeutics (CLDX)?
Celldex Therapeutics (CLDX) has a market capitalization of $1.79B. The average daily trading volume is 26.94, indicating the stock's liquidity and investor engagement.
News
URTICARIA
CLINICAL TRIALS
PIPELINE
BIOLOGIC TREATMENTS
HEALTHCARE INFRASTRUCTURE
DIGITAL INNOVATIONS
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
CELLDEX THERAPEUTICS
BARZOLVOLIMAB
CHRONIC INDUCIBLE URTICARIA
PHASE 2 CLINICAL TRIAL
POSITIVE RESULTS
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
CELLDEX THERAPEUTICS
BARZOLVOLIMAB
CHRONIC INDUCIBLE URTICARIA
PHASE 2 CLINICAL TRIAL
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
CELLDEX THERAPEUTICS
ANALYST RATINGS
FINANCIAL PERFORMANCE
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
CALENDAR OF EVENTS
HEALTH
Celldex Therapeutics to Present at Jefferies Healthcare Conference
ANALYST RATINGS
Analyst Expectations For Celldex Therapeutics's Future